natgillin/translations-raw huggingface dataset:
The CD3-binding molecule or the pharmaceutical composition for the use of claim 17 wherein said autoimmune or inflammatory disease is selected from the group consisting of: type I insulin-dependent diabetes, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, myasthenia gravis, celiac's disease, Sjogren's syndrome, Grave's disease, Crohn's disease, autoimmune hepatitis, psoriasis, psoriatic arthritis, asthma, allergic rhinitis, effects from organ transplantation, or graft vs. host disease (GVHD). 
CD3-vezujuća molekula ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 17, naznačena time što navedena autoimuna ili inflamatorna bolest je izabrana iz grupe koja se sastoji od: inzulin ovisnog dijabetesa tip 1, reumatoidnog artritisa, sistemskog lupus eritematozisa, multiple skleroze, inflamatorne bolesti crijeva, mijastenije gravis, celijakije, Sjogrenovog sindroma, Gravesove bolesti, Crohnove bolesti, autoimunog hepatitisa, psorijaze, psorijatičkog artritisa, astme, alergijskog rinitisa, efekata transplantacije organa ili bolesti transplanta protiv domaćina (GVHD).
In some methods, if the synthetic retinal derivative is a 9-cis-retinyl ester comprising a monocarboxylic acid ester substituent, it is a 9-cis-retinyl C1 to C10 ester. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 2, naznačen time, da je to 9-cis-retinil ester Ci-C19 monokarboksilata.
An intrauterine system according to claim 1, characterized in that the diol component c) is a mixture of hydroquinone bis(2-hydroxyethyl)ether and a straight chain oligomer prepared from 1,6-hexanediol and e-caprolactone. 
Intrauterinski sustav u skladu s patentnim zahtjevom 1, naznačen time što je diolna komponenta c) mješavina hidrokinona bis(2-hidroksietil) etera i oligomera ravnog lanca proizvedenog od 1,6-heksandiola i e-kaprolaktona.
The method of claim 1, comprising the additional step of adding Hepatitis B surface antigen prior to the addition of IPV. 
Postupak u skladu s patentnim zahtjevima 1-7, naznačen time što uključuje dodatni korak dodavanja površinskog antigena virusa Hepatitisa B prije podešavanja pH ili prije dodavanja IPV.
5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of lung cancer, colon carcinoma, or erythroleukemia in a patient who is also administered paclitaxel or docetaxel. 
(b) 5-hidroksi-4-(5-hidroksi-4-(1-metil-1H-indol-5-11)-4H-1,2,4-triazol-3-il)-2-izopropilfenil dihidrogen fosfat, ili tautomer, ili njegova farmaceutski prihvatljiva sol, u proizvodnji lijeka za liječenje raka pluća, raka kolona, ili eritroleukemije u pacijentu kojem se također daje paclitaxel ili docetaxel.
A compound according to claim 1 or 2, wherein R1, R2, R3 and R4 represent C1-C4 alkyl, C1-C4 alkoxy, halogen, nitro, cyano, or trifluoromethyl; 
i R" predstavljaju C,-C, alkil, C,-C, alkoksi, halogen, nitro, cijano ili trifluorometil; ili njegova farmaceutski prihvatljiva sol.
The solid formulation according to claim 2 or 3, characterized in that the disintegrant/carrier is selected from the group consisting of lactose, starch, cellulose, microcrystalline cellulose and methylcellulose, preferably characterized in that the carriers are starch and lactose. 
Čvrsta formulacija prema patentnom zahtjevu 2 ili 4, naznačena time, da je dezintegrator/nosač odabran iz skupine koja se sastoji od laktoze, škroba, mikrokristalne celuloze i metilceluloze, a poželjno je naznačena time, da nosači su škrob 1 laktoza.
In an embodiment, the hydrobromic acid in acetic acid solution is from 10% to 36% hydrobromic acid in acetic acid. 
Postupak prema patentnom zahtjevu 4, naznačen time, da otopina bromovodične kiseline u octenoj kiselini jest 33%-tna bromovodična kiselina u octenoj kiselini.
In another preferred embodiment of the pharmaceutical methods of the invention, said pediatric Philadelphia chromosome positive or negative ALL patient is MRD-positive in complete hematological remission. 
Konstrukt za uporabu prema zahtjevu 4, naznačen time što navedeni dječji pacijent s ALL je MRD-pozitivan u potpunoj hematološkoj remisiji.
Glatiramer acetate for use according to any one of claims 2, 3, 8, 10, 12 or 13, wherein the 40mg dose of glatiramer acetate is in a prefilled syringe for self administration by the patient. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da čovjek kao pacijent nije primio terapiju glatiramer acetatom prije početka liječenja.
The starting material, i.e. 
Početni materijal tj.
The recombinant Mycobacterium bovis cell of claim 1 or 2, which is characterized as rBCG AUrec:: Hly+:: Hyg+. 
Rekombinantna Mycobacterium bovis stanica iz zahtjeva 1 ili 2, koja je okarakterizirana kao rBCG AUrec:: Hly+:: Hyg+.
preparing a compound of formula 28 via cyclization of a compound of formula 29; 
pripravu spoja s formulom 28 putem ciklizacije spoja s formulom 29;
or a suitable salt (e.g. a hydrochloride salt) thereof, wherein n, R2, R3 and R4 are as defined in formula (I); or 
(IIIa) ili njegovom prikladnom soli, pri čemu su q, R'", Ri R kako je definirano u formuli (Ta); ili (11) reakciju spoja s formulom
A is selected from 
A je odabrano od
The reaction was stirred under an atmosphere of nitrogen overnight at 95°C. The mixture was cooled and diluted with ethyl acetate. 
Reakcija se miješa u atmosferi dušika preko noći na 95% C. Smjesa se hladi i razrijedi etil-acetatom.
or a pharmaceutically acceptable salt thereof. 
[image] ili njegova farmaceutskli prihvatljiva sol.
Additives, such as alkali aluminates and alkali salts, silicates and hydroxides, for example, which additionally increase the pH value of the solution and consequently the reactivity of C5S2$, are particularly preferred and can be metered in an amount ranging from 0.1 to 10% by weight, preferably from 0.5 to 5% by weight, and still more preferably from 1 to 2% by weight. 
Vezivno sredstvo sukladno barem jednom zahtjevu 1 do 6, naznačeno time što vezivno sredstvo sadrži litijeve soli i hidrokside i/ili druge alkalijeve soli i hidrokside i alkalijeve silikate kao dodatke mješavini ili daljnje mješavine, s dodacima mješavini poput alkalijskih soli, silikata 1 hidroksida, koji povećavaju pH vrijednost otopine i posljedično reaktivnost C5S2$, osobito poželjnim.
with ethyl chloroformate to obtain a compound of the formula 
H,C s etil kloroformatom radi dobivanja spoja formule
The method of claim 1, wherein the compound has formula (II) 
2. Spoj u skladu s patentnim zahtjevom 1 formule (II)
The terms “arylalkyl”, “arylalkenyl” and “arylalkynyl” as used alone or as part of another group refer to alkyl, alkenyl and alkynyl groups as described above having an aryl substituent. 
Termini "arilalkil", "arilalkenil" ili "arilalkinil" kao što se upotrebljava samostalno ili kao dio druge skupine odnose se na alkil, alkenil i alkinil skupine kao što je gore opisano koje imaju aril supstituent.
Thickness of the intimal layer of the aorta 
Debljina unutarnjeg sloja aorte
The method of claim 1, wherein the cementitious reactive powder comprises, 100 parts Portland cement; 30 parts fly ash; 3 parts calcium sulfate dihydrate; 2-10 wt. % expanded and chemically coated perlite filler. 
Kompozicija za pripremanje cementne ploče koja sadrži kašu koja sadrži smjesu sljedećih komponenti: 35 do 60 mas % cementnog reaktivnog praha koji sadrži Portland cement, 2 do 10 mas %, na vlažnoj osnovi, ekspandiranog i kemijski obloženog vodonepropusnog i vodootpornog perlitnog punioca.
In still another embodiment of the invention, the aforementioned one or more stabilizing agents is selected from the group consisting of mannitol, lactose, sorbitol, xylitol, sucrose, trehalose, mannose, maltose, lactose, glucose, raffinose, cellobiose, gentiobiose, isomaltose, arabinose, glucosamine, fructose and combinations of these stabilizing agents. 
Formulacija prema zahtjevu 1, naznačena time da je jedno ili više sredstava za stabilizaciju izabrano iz grupe koju čine manitol, laktoza, sorbitol, ksilitol, saharoza, trehaloza, manoza, maltoza, laktoza, glukoza, rafinoza, celobioza, gentiobioza, izomaltoza, arabinoza, glukozamin, fruktoza i kombinacije ovih sredstava za stabilizaciju.
determining positions of the entry points based on an offset which is 1 larger than a number indicated by fourth information obtained from the bitstream; decoding the second slice segment which is located after the first slice segment in decoding order in the current picture using the stored context variables and the entry points, 
određivanje položaja ulaznih točaka na temelju pomaka koji je 1 veći od broja naznačenog četvrtom informacijom dobivenom iz toka bitova; dekodiranje trenutne slike na temelju pohranjenih varijabli konteksta i ulaznih točaka.
The apparatus according to claim 12, wherein the processor is further configured to selectively simulate to the sender that the recipient is indeed a mobile network subscriber based on one or more predetermined criteria. 
Uređaj prema zahtjevu 7, gdje je procesor (301) dalje podešen da selektivno simulira pošiljatelju da je primatelj uistinu pretplatnik mobilne telekomunikacijske mreže na temelju jednog ili više unaprijed određenih kriterija.
A process according to any preceding claim, wherein the process is sequential, and step (iii) takes place immediately after step (ii). 
Postupak u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu je postupak sekvencijalan, a korak (111) se odvija odmah nakon koraka (ii).
a coded block flag indicating whether the transformation residual block includes at least one non-zero effective transformation coefficient, wherein, when the coded block flag indicates that the transformation residual block includes the at least one non-zero effective transformation coefficient and a current sub residual block is a left-upper sub residual block, the bitstream further includes a significance map indicating a location of a non-zero transformation coefficient in the current sub residual block and level information of the non-zero transformation coefficient in the current sub residual block; 
kada zastavica kodiranog bloka označava da rezidualni blok transformacije sadrži barem jedan efektivni koeficijent transformacije koji nije nula, dobivanje koeficijenata transformacije prve jedinice frekvencijskog pojasa na temelju karte značajnosti koja ukazuje na mjesta efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa i informacije o razini efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa dobivenoj iz toka bitova;
The mean plasma concentrations of nebivolol after an oral dose of 1 tablet (5 mg nebivolol) of the test formulation or 1 tablet (5 mg nebivolol) of the reference formulation are plotted in figure-VI. 
Srednje plazma koncentracije nebivolola nakon oralnog uzimanja 1 tablete (5 mg nebivolola) test pripravka ili 1 tablete (5 mg nebivolola) referentnog pripravka nacrtani su na slici 1.
Use according to claim 13, wherein the composition is a pharmaceutical aerosol formulation comprising particles of ciclesonide in a therapeutically effective amount and a hydrofluorocarbon propellant, preferably selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and 0.01 to 5 % w/w based upon propellant of polar cosolvent and optionally a surfactant. 
Uporaba prema zahtjevu 13, naznačena time, da sastav lijeka je farmaceutska aerosolna formulacija koja sadrži čestice ciklesonida u terapeutski djelotvornoj količini i hidrofluorokarbonski stlačeni plin (propelant), poželjno odabran od 1,1,1,2-tetrafluoroetana, 1,1,1,2,3,3,3-heptafluoropropana i njihovih mješavina, te polarno kootapalo 1 opcijski tenzid u količini od 0,01 do 5 masenih % prema masi propelanta.
WO 89/04669 and European Patent Application Publication No. 
EP 05723607.7 Datum podnošenja europske prijave patenta:
regenerating the cation exchange chromatography column by flushing the column with purified water. 
regeneracija kromatografskog stupca kationske izmjene ispiranjem stupca pročišćenom vodom.
is selected from the group consisting of H; C1-6-alkyl; C2-6-alkenyl; C2-6-alkynyl; C3-6-cycloalkyl-C1-6-alkyl; C1-6-cycloalkyl; cyano-C1-6-alkyl; amino-C1-6-alkyl; benzyl; pyridyl; saturated 5 or 6 membered heterocyclic ring having 1 to 2 heteroatoms selected from N, O, and S, and wherein said N is optionally substituted with C1-6-alkyl; R33R33'N-C1-6-alkylenyl; and phenyl, said phenyl being optionally substituted 1 to 3 times with R34; wherein and R33' are both C1-3-alkyl, or R33 and R33' together with the nitrogen, to which they are attached, form a saturated 5 or 6 membered heterocyclic ring optionally comprising one further heteroatom selected from N, O, and S; 
je odabran iz grupe koju čine H; C1-6-alkil; C2-6-alkenil; C2-6-alkinil; C3-6-cikloalkil-C1-6-alkil; C1-6-cikloalkil; cijano-C1-6-alkil; amino-C1-6-alkil; benzil; piridil; zasićeni 5 ili 6-eročlani heterociklički prsten s 1 do 2 heteroatoma odabrana između N, O, i S, i gdje taj N je po izboru supstituiran s C1-6-alkil; R33R33’N-C1-6-alkilenil; i fenil, taj fenil je po izboru supstituiran 1 do 3 puta s R34; gdje R33 i R33’ su oba C1-3-alkil, ili R33 i R33’ zajedno s dušikom za koji su spojeni, formiraju zasićeni 5 ili 6-eročlani heterociklički prsten koji po izboru sadrži jedan dodatni heteroatom odabran između N, O, i S;
A process according to claims 3 and 4, characterised in that the filling medium is introduced into the groove structures (4) at a temperature which is significantly higher than the normal temperature. 
Postupak prema zahtjevima 3 i 4, naznačen time, da se punilo uvodi u brazdaste strukture (4) pri temperaturi koja je značajno viša od normalne temperature.
in the manufacture of a medicament for the treatment of a pulmonary disorder. 
naznačena time što su kristalni Oblik 1 i steroidno protuupalno sredstvo namijenjeni proizvodnji medikamenta za liječenje plućnog poremećaja.
coupling the compound of formula (XXI) with 2-pyrazinecarboxylic acid in the presence of TBTU and a tertiary amine in dichloromethane; 
(i) spajanja spoja formule (XXT) sa 2-pirazinkarboksilnom kiselinom u prisustvi TBTU i tercijarnog amina u diklorometanu;
Pharmaceutical composition according to Claim 1, which is a capsule packaged into a cold-formed blister (so-called cold blister /CFF/) of OPA/AL/PVC composite foil covered with an aluminium lidding foil, or into a blister of thermoformable damp-proof composite foil and covered with an aluminium lidding foil, or into a glass or polypropylene vessel equipped with an airtight container cap of polyethylene or polypropylene, comprising 10%-15% of amlodipine besylate, 10%-15% of bisoprolol fumarate, further 55%-65% of microcrystalline cellulose, 4%-6% of sodium starch glycolate, 1%-2% of magnesium stearate, 0.5%-1% of colloid silica based on the weight of the filling substance of the capsule. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je kapsula pakirani into a hladno oblikovani blister (tzv. hladni blister /CFF/) od OPA/AL/PVC kompozitne folije pokrivene aluminijskom pokrovnom folijom, ili u blister od thermoformable kompozitna folija otporna na vlagu, te pokriva aluminijskom pokrovnom folijom, ili u staklenu ili polipropilensku posudu opremljenu hermetički zatvarajućim spremničkim poklopcem od polietilena ili polipropilena, što sadrži 10%-15% amlodipin-besilata, 10%-15% bisoprolol-fumarata, dodatno 55%-65% mikrokristalne celuloze, 4%-6% karboksimetilškrob-natrija, 1%-2% magnezijevog stearata, 0,5%-1% koloidnog silicijevog dioksida na osnovi težine tvari za punjenje kapsule.
The method of any preceding claim, wherein: the interaction chamber has a plurality of fixed geometry channels into which the emulsion passes and in which the emulsion is accelerated under pressure to reduce the emulsion's oil droplet size and reduce the number of oil droplets having a size >1.2 µm; wherein channels in the interaction chamber include a plurality of substantially right-angled corners; and wherein the back pressure chamber has at least one fixed geometry channel into which the emulsion passes. 
Metoda prema bilo kojem od prethodnih zahtjeva, naznačena time da: komora za interakciju ima više kanala fiksne geometrije kroz koje emulzija prolazi i u kojima je emulzija ubrzana pod pritiskom da se smanji veličina uljnih kapljica i broj uljnih kapljica emulzije koje imaju veličinu > 1,2 µm; gdje kanali u komori za interakciju uključuju više uglavnom pravih kutova i gdje komora povratnog pritiska ima najmanje jedan kanal fiksne geometrije kroz koji emulzija prolazi.
A pharmaceutical composition according to claim 1, containing a mixture of the two active ingredients in a weight ratio of dexketoprofen to tramadol from 2:1 to 1:10, equivalent to a weight ratio of dexketoprofen trometamol to tramadol hydrochloride from 2.59:1 to 1:7.7. 
Farmaceutski pripravak prema patentnim zahtjevima 1-4, koji sadrži smjesu dvaju aktivnih sastojaka masenog omjera deksketoprofena i tramadola od 2:1 do 1:10, ekvivalent masenom omjeru deksketoprofen trometamola i tramadol hidroklorida od 2.59:1 do 1:7.7.
Floor panel according to claim 9 or 10, characterized in that the separate insert comprises a pivotable lock-up body. 
Podni panel sukladno zahtjevu 17, naznačen time što je traka na način da se zatvara škljocanjem pričvršćena u otvor (13).
A composition according to claim 35, wherein the GPR119 agonist and the DPP-IV inhibitor are in amounts sufficient to lower a blood glucose level in a subject. 
Pripravak u skladu sa zahtjevom 32, naznačen time, da GPR119 agonist i DPP-IV inhibitor su u količinama dovoljnim da snize nivo glukoze u krvi kod subjekta.
The method according to any one of clauses 1-2, wherein said compound of Formula I is administered in a daily dose of about 3 to about 20 mg/day. 
Spoj za uporabu sukladno patentnom zahtjevu 1, pri čemu se navedeni spoj primjenjuje u dnevnoj dozi od oko 3 do oko 20 mg/dnevno.
The method as recited in statement 10, wherein the metal object comprises an electroplated metal layer with embedded luminescent particles configured to emit the energy comprising the second wavelength when excited by the energy comprising the first wavelength. 
Metalna podloga u skladu s patentnim zahtjevom 7, naznačen time što uklopljene luminiscentne čestice imaju sastav podešen za emitiranje energije druge valne duljine kada ih se pobudi energijom prve valne duljine.
The vial adapter element according to claim 1, wherein said biasing device comprises a coil spring. 
Adapter za bočicu (10) sukladno zahtjevu 1, naznačen time da se prednaponski sklop (30, 30A) sastoji od spiralne opruge.
fed under pressure to a second filter 14a of the first station 15a, with minimum passage aperture of 50 micron; 
- < dopremi se pod tlakom do drugog filtra 14a prve stanice 15a, s minimalnim otvorom prolaza od 50 mikrona;
The C1-2 perhalogenated alkyl group represents an alkyl group wherein all the hydrogen have been substituted by a halogeno, for example a CF3 or C2F5; 
Perhalogenirana C,.> alkilna skupina predstavlja alkilnu skupinu gdje su svi vodici zamijenjeni halogenima, primjerice CF; ili CoFs.
A pharmaceutical composition for cancer treatment characterized by comprising at least one antibody selected from the antibodies according to claims 1 to 36. 
Farmaceutska kompozicija za liječenje raka naznačena time da sadrži najmanje jedno antitijelo izabrano od antitijela u skladu sa patentnim zahtjevima 1 do 34.
a solid-state 13C NMR spectrum with signals at 123.1, 124.8 and 132.8 ± 0.2 ppm; or 
13C-NMR spektra čvrstog stanja, sa signalima na 112,3, 163,9, 168,8 ± 0,2 ppm;
Final compounds can be prepared by removal of the benzyl protecting group under oxidative conditions in a solvent like DMSO using a base such as potassium t-butoxide and oxygen gas. 
Konačni spojevi se mogu pripremiti uklanjanjem benzil zaštitne skupine uz oksidativne uvjete u otapalu poput DMSO uporabom baze poput kalij t- butoksida i plinovitog kisika.
Use according to any one of claims 1 to 6, wherein said ionizing radiations are selected in the group consisting of X-Rays, Y-Rays, electron beams and radioisotope emissions. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu su navedena ionizirajuća zračenja odabrana iz grupe koja se sastoji od X-zračenja, y-zračenja, elektronskih zraka i radioizotopnih emisija.
the single nucleotide polymorphism marker having a T at the position corresponding to position 312 in SEQ ID NO:3, 
ken dmoiien jednostrukog nukleotida koji ima T na položaju koji odgovara položaju 312 u SEQ ID NO:3,
Regarding the heat transport system of the preceding paragraph, in certain embodiments the at least one heat exchanger, the fluid conduit, and the heat transport fluid are arranged to maintain a set point temperature or set point temperature range of a chamber or surface without operation of the forced convection unit during steady state operation when the temperature of the ambient environment does not exceed the ambient environment threshold temperature or ambient environment threshold temperature range. 
Sustav prijenosa topline prema bilo kojem od zahtjeva 1 ili 2, naznačen time, da su najmanje jedan izmjenjivač topline, fluidni cjevovod i fluid za prijenos topline, raspoređeni za održavanje potrebne temperaturne vrijednosti ili potrebnog raspona temperaturne vrijednosti za komoru ili za površinu, bez djelovanja uređaja za prisilno toplinsko strujanje za vrijeme rada u stabilnom stanju, kada temperaturna vrijednost okolnog prostora ne prelazi graničnu temperaturnu vrijednost okolnog prostora ili ne prelazi granični raspon temperaturne vrijednosti okolnog prostora.
A compound of formula (III), a salt, or stereoisomer thereof, wherein, R1 is hydrogen or C1-6alkyl; 
Spoj formule (III), njegova sol ili njegov stereoizomer [image], naznačen time što: je vodik ili C1-6alkil;
an arithmetic decoder which is configured of obtaining a prefix bitstring of the last coefficient location among the information about a last coefficient location by performing context-based arithmetic decoding on the bitstream, and, when the prefix bitstring is greater than a predetermined value, obtaining, from the bitstream, a suffix bitstring according to a bypass mode; an inverse-binarizer which is configured to performing inverse binarization on the prefix bitstring according to truncated bizarization scheme to obtain an inverse-binarized prefix, and performing inverse binarization on the suffix bitstring according to fixed-length bizarization scheme to obtain an inverse-binarized suffix; and 
aritmetički dekoder koji je konfiguriran za provođenje kontekstnog aritmetičkog dekodiranja na prefiksu niza bitova mjesta zadnjeg značajnog koeficijenta između informacija o mjestu zadnjeg značajnog koeficijenta, i, kada je prefiks niza bitova veći od prethodno određene vrijednosti, provođenje zaobilaznog načina aritmetičkog dekodiranja na sufiksu niza bitova mjesta zadnjeg značajnog koeficijenta između informacija o mjestu zadnjeg značajnog koeficijenta;
A product comprising (a) a PDE4 inhibitor as defined in any one of claims 1 and 3 to 6 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Proizvod koji sadrži (a) P2 agonist kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 7 i (b) antagonist M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačen time, da je to proizvod u obliku kombiniranog pripravka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnika koji su oboljeli ili bi mogli oboljeti od bolesti dišnih putova koje su definirane u patentnom zahtjevu 11 ili 12.
thermal calendered polypropylene fibers, with a basis weight ranging from 100 g/m2 to 1000 g/m2, 
toplinski kalandrirana polipropilenska vlakna, s osnovnom težinom od 100g/m² do 1000g/m²